At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
arsenic trioxidedrug
Likely dose
Arsenic trioxide, intravenous, dose not specifiedAI-extracted
Key inclusion· 5
- ✓Basal cell carcinoma (BCC) diagnosis
- ✓Ineligible for curative surgery/radiation and failed, intolerant, or ineligible for smoothened antagonists (vismodegib, XL 139, IPI-926, LDE225, PF-04449913)
- ✓Life expectancy >3 months
- ✓ECOG performance status 0-2
Key exclusion· 4
- ✕Concurrent use of other investigational agents
- ✕Cardiac arrhythmias or prolonged QTc
- ✕Uncontrolled intercurrent illness including active infection, symptomatic heart failure, unstable angina, arrhythmia, recurrent seizures, or psychiatric illness affecting compliance
- ✕Pregnancy or lactation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating arsenic trioxide for Basal Cell Carcinoma of the Skin and Recurrent Skin Cancer. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsThe V Foundation for Cancer Research
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartApr 2013
Primary CompletionNov 2013
Study CompletionNov 2015
TodayJul 2026
First PostedFeb 15, 2013
Enrollment StartApr 1, 2013
Primary CompletionNov 1, 2013
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.4 years ago
Interventions
arsenic trioxidedrug
Given IV